You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

CLINICAL TRIALS PROFILE FOR TELAGLENASTAT

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Telaglenastat

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02771626 ↗	Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)	Completed	Calithera Biosciences, Inc	Phase 1/Phase 2	This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
NCT03057600 ↗	Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)	Completed	Calithera Biosciences, Inc	Phase 2	CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in patients of African ancestry and non-African ancestry with advanced triple negative breast cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839 will be administered in combination with the full approved dose of paclitaxel.
NCT03163667 ↗	ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With Renal Cell Carcinoma (RCC)	Completed	Calithera Biosciences, Inc	Phase 2	Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic RCC
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Telaglenastat

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Clear Cell Renal Cell Carcinoma	3
NFE2L2 Gene Mutation	2
CRC	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Carcinoma	5
Carcinoma, Renal Cell	4
Carcinoma, Non-Small-Cell Lung	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Telaglenastat

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	179
United Kingdom	6
Australia	5
New Zealand	3
Germany	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Texas	9
Pennsylvania	9
New York	9
Florida	8
Massachusetts	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Telaglenastat

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
PHASE1	1
Phase 2	7
Phase 1/Phase 2	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	7
Recruiting	5
Not yet recruiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Telaglenastat

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Calithera Biosciences, Inc	11
National Cancer Institute (NCI)	6
Synhale Theraputics	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	13
NIH	6
Other	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.